Amiodarone is an established therapeutic option for AF (Hamilton et al., 2020), but it bears significant interaction potential: (i) inhibition of cardiac potassium channels (hERG-channel) for QTc prolongation, (ii) inhibition of various cytochrome P450 (CYP) enzymes and (iii) of P-glycoprotein (Hamilton et al., 2020; Harder and Thürmann, 1996; Taylor, 2002). The gene discussed is ABCB1; the disease is atrial fibrillation.